


#11
6/3/03



Express Mail No. **EV333999778US**

RECEIVED
MAY 28 2003
TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Address to:
Commissioner for Patents
Washington, D.C. 20231

| | |
|---|-----------------|
| Attorney Docket (Confirmation No.) | ROCH007 4701 |
| First Named Inventor | A. Grupe |
| Application Number | 09/925,547 |
| Filing Date | August 8, 2001 |
| Group Art Unit | 1632 |
| Examiner Name | P. Paras |
| Title: <i>Methods and compositions for treating gastrointestinal tract mucin production associated disease conditions</i> | |

Sir:

This is in response to the Restriction Requirement dated April 23, 2003. The Restriction Requirement set forth a one-month time period for response, making a response due on or before May 23, 2003. Accordingly, this response is timely filed.

I. REMARKS

In the Restriction Requirement, the Examiner required election of one of the following groups of claims:

- Group I: Claims 1-5 and 8-11, drawn to a method of treating a subject having a disease state associated with a mucus secretion disorder, wherein the disease state is associated with mucus hypersecretion;
- Group II: Claims 1,6-7, and 8-11, drawn to a method of treating a subject having a disease state associated with a mucus secretion disorder, wherein the disease state is associated with mucus hyposecretion;
- Group III: Claims 12 and 14-15, drawn to a method of screening for a compound that modulates CaCC activity in a cell free system;
- Group IV: Claims 12-15, drawn to a method of screening for a compound that modulates CaCC activity in a cell;
- Group V: Claims 12-15, drawn to a method of screening for a compound that modulates CaCC activity on a solid support;
- Group VI: Claims 16-17, drawn to an unidentified compound;
- Group VII: Claims 18-21, drawn to a transgenic non-human animal comprising an altered CaCC gene;